Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Has Consensus Target Price of $9.17 According to Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) have received an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $9.17.

AQST has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, September 10th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th.

Get Aquestive Therapeutics alerts:

Check Out Our Latest Stock Report on Aquestive Therapeutics

Insiders Place Their Bets

In other Aquestive Therapeutics news, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the sale, the insider directly owned 235,689 shares in the company, valued at $1,230,296.58. This represents a 3.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $4.82, for a total value of $120,500.00. Following the completion of the sale, the chief executive officer directly owned 652,317 shares of the company’s stock, valued at $3,144,167.94. This trade represents a 3.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. WINTON GROUP Ltd purchased a new position in Aquestive Therapeutics during the second quarter worth about $210,000. Engineers Gate Manager LP grew its stake in shares of Aquestive Therapeutics by 20.5% in the 2nd quarter. Engineers Gate Manager LP now owns 49,879 shares of the company’s stock valued at $207,000 after buying an additional 8,496 shares during the period. Wedbush Securities Inc. acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $60,000. Wellington Management Group LLP increased its holdings in shares of Aquestive Therapeutics by 4.0% during the 2nd quarter. Wellington Management Group LLP now owns 301,647 shares of the company’s stock worth $1,255,000 after buying an additional 11,587 shares during the last quarter. Finally, Beacon Pointe Advisors LLC purchased a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at approximately $252,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 0.9%

Shares of AQST opened at $4.61 on Friday. Aquestive Therapeutics has a 52-week low of $2.93 and a 52-week high of $7.55. The firm’s fifty day moving average is $4.62 and its two-hundred day moving average is $4.32. The stock has a market cap of $578.60 million, a PE ratio of -7.09 and a beta of 1.49.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. As a group, research analysts anticipate that Aquestive Therapeutics will post -0.5 earnings per share for the current year.

Aquestive Therapeutics Company Profile

(Get Free Report)

Aquestive Therapeutics, Inc is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.

Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders.

Featured Stories

• Five stocks we like better than Aquestive Therapeutics
• Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
• Lamb Weston’s Turnaround Is Starting to Look Real
• These 3 Stocks Got the Most Love From Analysts in September
• Record French Debt Could Create Opportunities for U.S. Market Operators

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.